ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

This study is currently recruiting participants.
Verified by Mayo Clinic, December 2007

Sponsored by: Mayo Clinic
Information provided by: Mayo Clinic
ClinicalTrials.gov Identifier: NCT00589394
  Purpose

The lack of clear guidelines and studies addressing the proper response to the pneumococcal vaccine (Pneumovax ®) has hampered our ability to diagnosis and care for our immunodeficiency patients. Should an age matched normal response range to the Pneumovax ® be established, it would have a profound impact in the diagnosis, safety and care of immunodeficiency patients. Moreover, characterizing the B cell compartments response to the Pneumovax ® may better delineate the mechanism of protective immunity from Pneumovax ® and provide an additional tool for the diagnosis and care for immunodeficiency patients.


Condition Intervention
Healthy
Other: pneumococcal vaccination (Pneumovax)

ChemIDplus related topics:   Heptavalent pneumococcal conjugate vaccine    Pneumococcal Vaccines   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Diagnostic, Non-Randomized, Open Label, Single Group Assignment
Official Title:   Analysis of the Mechanisms of Protective Humoral Immunity in Response to the Pneumococcal Vaccine

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Assess IgG antibodies to pneumococcus pre- and post-pneumococcal immunization in healthy controls [ Time Frame: 4-6 wks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Analysis of B cell subsets in blood of healthy controls pre-and post-pneumococcal immunization to identify changes in memory B cell, class switched and activated B cells. [ Time Frame: 4-6 wks ] [ Designated as safety issue: No ]

Estimated Enrollment:   100
Study Start Date:   July 2007
Estimated Primary Completion Date:   July 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
1: Experimental
Pneumovax is given and the pre and post pneumococcal serology are drawn
Other: pneumococcal vaccination (Pneumovax)
pneumovax

Detailed Description:

The ability to respond to a polysaccharide vaccine antigen is an integral part of evaluating a patient with immunodeficiency [1]. The pneumococcal vaccine (Pneumovax ®) remains the only readily available and the most widely used unconjugated polysaccharide vaccine [2]. Although the pneumococcal vaccine is widely used test the immune systems response to a polysaccharide antigen, no clear guidelines or studies exist to what is considered a proper response to the Pneumovax ®. IgM memory B cells are thought to play an important role in protection against pneumococcal disease. It is not known to what extent the ability of B cells to be activated in response to pneumococcal vaccination contributes to protective immunity. To address these issues, the following two specific aims are proposed:

Specific Aim 1. Assess IgG antibodies to pneumococcus pre- and post-pneumococcal immunization in healthy controls Specific Aim 2. Analysis of B cell subsets in blood of healthy controls pre-and post-pneumococcal immunization to identify changes in memory B cell, class switched and activated B cells.

  Eligibility
Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Patients from 20 to 70 years of age

Exclusion Criteria:

  • Previous or current diagnosis of an immunodeficiency (primary and secondary)
  • Previous or current diagnosis of a rheumatological disorders (Rheumatoid arthritis, Lupus, Sjögren, vasculitis), cancer, diabetes, active infection and/or other chronic diseases (multiple sclerosis, etc)
  • Current or previous use (within that last 6 months) of systemic/inhaled corticosteroids, sulfasalazine, and other immunosuppressive agents (cyclosporin, methotrexate, CellCept) anti-convulsants (phenytoin, carbamazepine), gold, d-penicillamine, and anti-malarials (quinine, chloroquine, hydroxychloroquine)
  • Pregnancy
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00589394

Contacts
Contact: kay bachman, rn     507-284-1903     bachman.kay@mayo.edu    

Locations
United States, Minnesota
Mayo clinic     Recruiting
      rochester, Minnesota, United States, 55902
      Contact: kay bachman, rn     507-284-1903     bachman.kay@mayo.edu    
      Principal Investigator: miguel park, md            
      Principal Investigator: miguel park, md            

Sponsors and Collaborators
Mayo Clinic

Investigators
Principal Investigator:     miguel park, md     Mayo Clinic    
  More Information


Mayo Clinic Clinical Trials  This link exits the ClinicalTrials.gov site
 

Responsible Party:   mayo clinic ( Miguel Park )
Study ID Numbers:   07-004799
First Received:   December 28, 2007
Last Updated:   January 8, 2008
ClinicalTrials.gov Identifier:   NCT00589394
Health Authority:   United States: Institutional Review Board

Keywords provided by Mayo Clinic:
pneumoccal vaccine  
normal response  
immunodeficiency  
Healthy patients  
Healthy Volunteers  

Study placed in the following topic categories:
Healthy
Immunologic Deficiency Syndromes

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers